I am an early-mid career researcher (PhD 2012 with 2FTE career disruption) and a Senior Research Fellow whose work spans basic science, translational and clinical research.

In the last 10 years I have achieved: 

• An International Patent (WO/2018/107241) on innovative peptide-based therapeutics.
• 47 high-impact career publications in top-tier journals (h-index: 27; >15,000 citations [Google Scholar]), such as Blood, PNAS USA, Autophagy, Redox Biol, Antioxid Redox Signal, Free Radic Biol Med, Pharmacol Res. Integral 1st/2nd/senior author on 44% of my publications.
• Field-Weighted Citation Impact (FWCI): 3.51, i.e., 3.51 times more cited than the World average; 48% in Top 10% Most Cited Publications; 61% in Top 10% Journals (Scopus SciVal). In the last 5 years, I have 25 publications, >8000 citations, FWCI: 5.43.

Multidisciplinary research is central to my work. Originally trained as a bioinformatician that bridges the disciplines of computer science and biology, I was awarded a PhD in Pathology at the University of Sydney where I applied my bioinformatics knowledge and expand upon my skills in molecular biology, biochemistry, animal preclinical models and human histopathology for the investigation of a rare, but fatal mitochondrial heart disease due to disrupt iron metabolism and oxidative stress.

In recent years working with renowned clinician-scientists: my mentors Prof Alicia Jenkins (Baker Institute), Dr Anastasia Mihailidou (Kolling Inst/RNSH), and Prof Anthony Keech (USyd/RPAH), A/Prof Sean Lal (USyd/RPAH), I gained invaluable experience in clinical heart and diabetes research. I look forward to collaborating with leading researchers at the Baker Institute, while bringing my accumulated multidisciplinary skillset to supplement the wonderful heart and diabetes research being accomplished here.